Praxis Precision Medicines, Inc. Common Stock (PRAX) is a publicly traded Healthcare sector company. As of May 20, 2026, PRAX trades at $335.76 with a market cap of $8.94B and a P/E ratio of -24.76. PRAX moved +4.66% today. Year to date, PRAX is +21.19%; over the trailing twelve months it is +745.37%. Its 52-week range spans $26.70 to $358.76. Analyst consensus is strong buy with an average price target of $643.38. Rallies surfaces PRAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Truist Initiates Praxis Coverage with $715 Target, 112% Upside and FDA NDA Acceptances: Truist initiated coverage on Praxis Precision Medicines with a Buy rating and $715 price target, implying 112% upside. The company holds $1.4 billion cash, has two FDA‐accepted NDAs with PDUFA dates in September 2026 and January 2027 and reported a 77% seizure reduction in EMBRAVE Part A.
| Metric | Value |
|---|---|
| Price | $335.76 |
| Market Cap | $8.94B |
| P/E Ratio | -24.76 |
| EPS | $-13.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $358.76 |
| 52-Week Low | $26.70 |
| Volume | 230.75K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-303.27M |
| Gross Margin | 0.00% |
16 analysts cover PRAX: 0 strong buy, 14 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $643.38.